Trials / Completed
CompletedNCT00232024
Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,296 (planned)
- Sponsor
- Novartis · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This study is being done to evaluate the safety, tolerability and satisfactory relief of dyspepsia symptoms in females excluding those with predominant stomach pain. Tegaserod will be evaluated at 6mg twice daily and placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tegaserod |
Timeline
- Start date
- 2004-01-01
- Completion
- 2006-05-01
- First posted
- 2005-10-04
- Last updated
- 2008-02-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00232024. Inclusion in this directory is not an endorsement.